Search for: "Schering AG"
Results 81 - 89
of 89
Sorted by Relevance
|
Sort by Date
18 Jun 2012, 7:28 am
A possibilidade de indenização por dano moral está prevista na Constituição Federal, em seu artigo 5º, inciso V. [read post]
28 Apr 2008, 11:00 am
: (Patent Docs), US: Supreme Court declines to hear final Nucleonics’ appeal in gene-silencing patent dispute with Benitec Australia: (IP Law360), (Therapeutics Daily), US: 505(b)(2) drug approvals rock - Interaction of patents and exclusivity of drugs approved by FDA under section 505(b)(2): (Patent Baristas), US: StemCells’ patents survive reexam – StemCells and Neuralstem differ on extent of changes: (Patent Docs), US: StemCells announces issuance of… [read post]
25 Jun 2009, 4:29 am
This post is largely about drug and medical device litigation "inside baseball. [read post]
3 Apr 2009, 7:23 pm
Here is IP Think Tank’s weekly selection of top intellectual property news breaking in the blogosphere and internet. [read post]
3 Jul 2008, 7:26 pm
Regular readers know that we've been keeping two "scorecards" - one for drug preemption, and one for device preemption. [read post]
16 Oct 2009, 3:18 pm
Dietary supplement claims must be substantiated by scientific evidence, the FDA has guidance for industry about this. [read post]
19 Sep 2008, 6:00 pm
: (IP finance), United States: An open letter for the General Counsel of the PTO on your San Diego presentation next week: (Hal Wegner), United States: Cocoa genome: breaking intellectual property barriers: (Thomson Reuters Scientific), Vietnam: Patentability of second medical use claims in Vietnam is again questionable: (Trung Truc JSC) Pharma & Biotech - Products Allegra (Fexofenadine) - Canada: Motion for summary judgment of noninfringement dismissed in patent infringement… [read post]
15 Mar 2008, 7:00 am
India: Gene silencing: (Spicy IP), India: US Patent reform implications for Indian Pharma: (Spicy IP), India: Generic pharmaceutical industry in the spotlight: (International Law Office), India: Supreme Court refuses to stay a Gujarat High Court decision restraining Ranbaxy from airing its controversial ads directed against Paras Pharma's 'Moov' brand: (Spicy IP),India: Patents on ARV drugs could increase costs: (Generic Pharmaceuticals & IP),US: Survey shows most Americans… [read post]
12 May 2015, 3:26 pm
Brokerage firms that sell RCNs are required to evaluate whether they are suitable given the investor’s age, risk tolerance and investment objectives, net worth, and investment experience. [read post]
